Lipoxygenase: An emerging target for stroke therapy

CNS and Neurological Disorders - Drug Targets

Volumn 12, Issue 2, 2013, Pages 191-199

  van Leyen, Klaus ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Arachidonic acid cascade; Eicosanoid; Ischemic stroke; Lipoxygenase; Neuroprotection; Oxidative stress

Indexed keywords

12 HYDROXYICOSATETRAENOIC ACID; 2 AMINO N (3 CHLOROPHENYL) 4,5,6,7 TETRAHYDRO 1 BENZOTHIOPHENE 3 CARBOXAMIDE; 4 ETHYL 6 (4 PHENOXY 1H PYRAZOL 3 YL) 1,3 BENZENEDIOL; ALPHA TOCOTRIENOL; APOPTOSIS INDUCING FACTOR; ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; BAICALEIN; CD59 ANTIGEN; COPPER ZINC SUPEROXIDE DISMUTASE; CURCUMIN; CYTOCHROME P450; EPIGALLOCATECHIN GALLATE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; ICOSANOID; LIPOXIN; LIPOXYGENASE INHIBITOR; MANGANESE SUPEROXIDE DISMUTASE; NORPHENAZONE; PEROXIREDOXIN 2; PHOSPHOLIPASE A2; PROSTAGLANDIN SYNTHASE; PROTEASOME; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

BLOOD FLOW; BLOOD VESSEL INJURY; CALCIUM TRANSPORT; CELL DEATH; CEREBROVASCULAR ACCIDENT; DISEASE SEVERITY; ENZYME INHIBITION; EXCITOTOXICITY; GENE INACTIVATION; IMMUNOHISTOCHEMISTRY; NERVE CELL; NEUROPROTECTION; NONHUMAN; OXIDATION; OXIDATIVE STRESS; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ARACHIDONIC ACID; ENZYME INHIBITORS; HUMANS; LIPOXYGENASE; MODELS, BIOLOGICAL; STROKE;

EID: 84876715502     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/18715273112119990053     Document Type: Review

References (124)

1. Shuaib, A.; Lees, K.R.; Lyden, P.; Grotta, J.; Davalos, A.; Davis, S.M.; Diener, H.C.; Ashwood, T.; Wasiewski, W.W.; Emeribe, U. NXY-059 for the treatment of acute ischemic stroke. N. Engl. J. Med., 2007, 357, 562-571.
2. Moskowitz, M.A.; Lo, E.H. Iadecola, C. The science of stroke: mechanisms in search of treatments. Neuron, 2010, 67, 181-198.
3. Zlokovic, B.V.; Griffin, J.H. Cytoprotective protein C pathways and implications for stroke and neurological disorders. Trends Neurosci., 2011, 34, 198-209.
4. Quaegebeur, A.; Lange, C.; Carmeliet, P. The neurovascular link in health and disease: molecular mechanisms and therapeutic implications. Neuron, 2011, 71, 406-424.
5. Lau, A.; Tymianski, M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch., 2010, 460, 525-542.
6. Besancon, E.; Guo, S.; Lok, J.; Tymianski, M.; Lo, E.H. Beyond NMDA and AMPA glutamate receptors: emerging mechanisms for ionic imbalance and cell death in stroke. Trends Pharmacol. Sci., 2008, 29, 268-275.
7. Haeggstrom, J.Z.; Rinaldo-Matthis, A.; Wheelock, C.E.; Wetterholm, A. Advances in eicosanoid research, novel therapeutic implications. Biochem. Biophys. Res. Commun., 2010, 396, 135-139.
8. Nigam, S.; Zafiriou, M.P.; Deva, R.; Ciccoli, R.; Roux-Van der Merwe, R. Structure, biochemistry and biology of hepoxilins: an update. FEBS J., 2007, 274, 3503-3512.
9. Pace-Asciak, C.R. The hepoxilins and some analogues: a review of their biology. Br. J. Pharmacol., 2009, 158, 972-981.
10. Serhan, C.N. Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Prostaglandins Leukot. Essent. Fatty Acids, 2005, 73, 141-162.
11. Brash, A.R. Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. J. Biol. Chem., 1999, 274, 23679-23682.
12. Lo, E.H.; Moskowitz, M.A.; Jacobs, T.P. Exciting, radical, suicidal: how brain cells die after stroke. Stroke, 2005, 36, 189-192.
13. Bazan, N.G., Jr. Effects of ischemia and electroconvulsive shock on free fatty acid pool in the brain. Biochim. Biophys. Acta, 1970, 218, 1-10.
14. Chan, P.H.; Fishman, R.A. Brain edema: induction in cortical slices by polyunsaturated fatty acids. Science, 1978, 201, 358-360.
15. Chan, P.H.; Fishman, R.A.; Caronna, J.; Schmidley, J.W.; Prioleau, G.; Lee, J. Induction of brain edema following intracerebral injection of arachidonic acid. Ann. Neurol., 1983, 13, 625-632.
16. Moskowitz, M.A.; Kiwak, K.J.; Hekimian, K.; Levine, L. Synthesis of compounds with properties of leukotrienes C4 and D4 in gerbil brains after ischemia and reperfusion. Science, 1984, 224, 886-889.
17. Li, Y.; Maher, P.; Schubert, D. A role for 12-lipoxygenase in nerve cell death caused by glutathione depletion. Neuron, 1997, 19, 453-463.
18. van Leyen, K.; Lee, S.R.; Siddiq, A.; Ratan, R.R.; Lo, E.H. 12/15- lipoxygenase and the proteasome as mediators of neuronal oxidative stress and stroke. Program No 1356, 2004 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience, 2004.
19. Khanna, S.; Roy, S.; Slivka, A.; Craft, T.K.; Chaki, S.; Rink, C.; Notestine, M.A.; DeVries, A.C.; Parinandi, N.L.; Sen, C.K. Neuroprotective properties of the natural vitamin E alphatocotrienol. Stroke, 2005, 36, 2258-2264.
20. van Leyen, K.; Kim, H.Y.; Lee, S.R.; Jin, G.; Arai, K.; Lo, E.H. Baicalein and 12/15-lipoxygenase in the ischemic brain. Stroke, 2006, 37, 3014-3018.
21. Poloyac, S.M.; Reynolds, R.B.; Yonas, H.; Kerr, M.E. Identification and quantification of the hydroxyeicosatetraenoic acids, 20-HETE and 12-HETE, in the cerebrospinal fluid after subarachnoid hemorrhage. J. Neurosci. Methods, 2005, 144, 257-263.
22. Farias, S.E.; Heidenreich, K.A.; Wohlauer, M.V.; Murphy, R.C.; Moore, E.E. Lipid mediators in cerebral spinal fluid of traumatic brain injured patients. J. Trauma, 2011, 71, 1211-1218.
23. Yigitkanli, K.; Pekcec, A.; Karatas, H.; Pallast, S.; Mandeville, E.; Joshi, N.; Smirnova, N.; Gazaryan, I.; Ratan, R.R.; Witztum, J.L.; Montaner, J.; Holman, T.R.; Lo, E.H.; van Leyen, K. Inhibition of 12/15-Lipoxygenase as Therapeutic Strategy to Treat Stroke. Ann. Neurol., 2013, 73, 129-135.
24. Pallast, S.; Arai, K.; Pekcec, A.; Yigitkanli, K.; Yu, Z.; Wang, X.; Lo, E.H.; van Leyen, K. Increased nuclear apoptosis-inducing factor after transient focal ischemia: a 12/15-lipoxygenasedependent organelle damage pathway. J. Cereb. Blood Flow Metab., 2010, 30, 1157-1167.
25. Jin, G.; Arai, K.; Murata, Y.; Wang, S.; Stins, M.F.; Lo, E.H.; van Leyen, K. Protecting against cerebrovascular injury: contributions of 12/15-lipoxygenase to edema formation after transient focal ischemia. Stroke, 2008, 39, 2538-2543.
26. Schewe, T.; Rapoport, S.M.; Kuhn, H. Enzymology and physiology of reticulocyte lipoxygenase: comparison with other lipoxygenases. Adv. Enzymol. Relat. Areas Mol. Biol., 1986, 58, 191-272.
27. Ivanov, I.; Heydeck, D.; Hofheinz, K.; Roffeis, J.; O'Donnell, V.B.; Kuhn, H.; Walther, M. Molecular enzymology of lipoxygenases. Arch. Biochem. Biophys., 2010, 503, 161-174.
28. Maccarrone, M.; Melino, G.; Finazzi-Agro, A. Lipoxygenases and their involvement in programmed cell death. Cell Death Differ., 2001, 8, 776-784.
29. van Leyen, K.; Duvoisin, R.M.; Engelhardt, H.; Wiedmann, M. A function for lipoxygenase in programmed organelle degradation. Nature, 1998, 395, 392-395.
30. van Leyen, K. Pictures in cell biology. Un-LOXing the door to organelle degradation. Trends Cell Biol., 1998, 8, 436.
31. Grüllich, C.; Duvoisin, R.M.; Wiedmann, M.; van Leyen, K. Inhibition of 15-lipoxygenase leads to delayed organelle degradation in the reticulocyte. FEBS Lett., 2001, 489, 51-54.
32. Schewe, T.; Halangk, W.; Hiebsch, C.; Rapoport, S.M. A lipoxygenase in rabbit reticulocytes which attacks phospholipids and intact mitochondria. FEBS Lett., 1975, 60, 149-52.
33. Bassnett, S. On the mechanism of organelle degradation in the vertebrate lens. Exp. Eye Res., 2009, 88, 133-139.
34. Dahm, R. Dying to see. Sci. Am., 2004, 291, 82-89.
35. Conrad, D.J.; Lu, M. Regulation of human 12/15-lipoxygenase by Stat6-dependent transcription. Am. J. Respir. Cell Mol. Biol., 2000, 22, 226-234.
36. Huang, J.T.; Welch, J.S.; Ricote, M.; Binder, C.J.; Willson, T.M.; Kelly, C.; Witztum, J.L.; Funk, C.D.; Conrad, D.; Glass, C.K. Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature, 1999, 400, 378-382.
37. Shureiqi, I.; Zuo, X.; Broaddus, R.; Wu, Y.; Guan, B.; Morris, J.S.; Lippman, S.M. The transcription factor GATA-6 is overexpressed in vivo and contributes to silencing 15-LOX-1 in vitro in human colon cancer. FASEB J., 2007, 21, 743-753.
38. Ostareck, D.H.; Ostareck-Lederer, A.; Shatsky, I.N.; Hentze, M.W. Lipoxygenase mRNA silencing in erythroid differentiation: The 3'UTR regulatory complex controls 60S ribosomal subunit joining. Cell, 2001, 104, 281-290.
39. Ostareck, D.H.; Ostareck-Lederer, A.; Wilm, M.; Thiele, B.J.; Mann, M.; Hentze, M.W. mRNA silencing in erythroid differentiation: hnRNP K and hnRNP E1 regulate 15-lipoxygenase translation from the 3' end. Cell, 1997, 89, 597-606.
40. Brinckmann, R.; Schnurr, K.; Heydeck, D.; Rosenbach, T.; Kolde, G.; Kuhn, H. Membrane translocation of 15-lipoxygenase in hematopoietic cells is calcium-dependent and activates the oxygenase activity of the enzyme. Blood, 1998, 91, 64-74.
41. Imai, H.; Nakagawa, Y. Biological significance of phospholipid hydroperoxide glutathione peroxidase (PHGPx, GPx4) in mammalian cells. Free Radic. Biol. Med., 2003, 34, 145-169.
42. Uemura, Y.; Miller, J.M.; Matson, W.R.; Beal, M.F. Neurochemical analysis of focal ischemia in rats. Stroke, 1991, 22, 1548-1553.
43. Bano, D. Nicotera, P. Ca2+ signals and neuronal death in brain ischemia. Stroke, 2007, 38, 674-676.
44. Murphy, T.H.; Schnaar, R.L.; Coyle, J.T. Immature cortical neurons are uniquely sensitive to glutamate toxicity by inhibition of cystine uptake. FASEB J., 1990, 4, 1624-1633.
45. Ratan, R.R.; Murphy, T.H.; Baraban, J.M. Oxidative stress induces apoptosis in embryonic cortical neurons. J. Neurochem., 1994, 62, 376-379.
46. Ratan, R.R.; Ryu, H.; Lee, J.; Mwidau, A.; Neve, R.L. In vitro model of oxidative stress in cortical neurons. Methods Enzymol., 2002, 352, 183-190.
47. Wang, H.; Li, J.; Follett, P.L.; Zhang, Y.; Cotanche, D.A.; Jensen, F.E.; Volpe, J.J.; Rosenberg, P.A. 12-Lipoxygenase plays a key role in cell death caused by glutathione depletion and arachidonic acid in rat oligodendrocytes. Eur. J. Neurosci., 2004, 20, 2049-2058.
48. Zhang, Y.; Aizenman, E.; DeFranco, D.B.; Rosenberg, P.A. Intracellular zinc release, 12-lipoxygenase activation and MAPK dependent neuronal and oligodendroglial death. Mol. Med., 2007, 13, 350-355.
49. van Leyen, K.; Arai, K.; Jin, G.; Kenyon, V.; Gerstner, B.; Rosenberg, P.A.; Holman, T.R.; Lo, E.H. Novel lipoxygenase inhibitors as neuroprotective reagents. J. Neurosci. Res., 2008, 86, 904-909.
50. Pallast, S.; Arai, K.; Wang, X.; Lo, E.H.; van Leyen, K. 12/15- Lipoxygenase targets neuronal mitochondria under oxidative stress. J. Neurochem., 2009, 111, 882-889.
51. van Leyen, K.; Siddiq, A.; Ratan, R.R.; Lo, E.H. Proteasome inhibition protects HT22 neuronal cells from oxidative glutamate toxicity. J. Neurochem., 2005, 92, 824-830.
52. Tobaben, S.; Grohm, J.; Seiler, A.; Conrad, M.; Plesnila, N.; Culmsee, C. Bid-mediated mitochondrial damage is a key mechanism in glutamate-induced oxidative stress and AIFdependent cell death in immortalized HT-22 hippocampal neurons. Cell Death Differ., 2011, 18, 282-292.
53. Seiler, A.; Schneider, M.; Forster, H.; Roth, S.; Wirth, E.K.; Culmsee, C.; Plesnila, N.; Kremmer, E.; Radmark, O.; Wurst, W.; Bornkamm, G.W.; Schweizer, U.; Conrad, M. Glutathione peroxidase 4 senses and translates oxidative stress into 12/15- lipoxygenase dependent- and AIF-mediated cell death. Cell Metab., 2008, 8, 237-248.
54. Huang, H.S.; Chen, C.J.; Suzuki, H.; Yamamoto, S.; Chang, W.C. Inhibitory effect of phospholipid hydroperoxide glutathione peroxidase on the activity of lipoxygenases and cyclooxygenases. Prostaglandins Other Lipid Mediat., 1999, 58, 65-75.
55. Khanna, S.; Roy, S.; Parinandi, N.L.; Maurer, M.; Sen, C.K. Characterization of the potent neuroprotective properties of the natural vitamin E alpha-tocotrienol. J. Neurochem., 2006, 98, 1474-1486.
56. Khanna, S.; Roy, S.; Ryu, H.; Bahadduri, P.; Swaan, P.W.; Ratan, R.R.; Sen, C.K. Molecular basis of vitamin E action: tocotrienol modulates 12-lipoxygenase, a key mediator of glutamate-induced neurodegeneration. J. Biol. Chem., 2003, 278, 43508-43515.
57. Rink, C.; Christoforidis, G.; Khanna, S.; Peterson, L.; Patel, Y.; Abduljalil, A.; Irfanoglu, O.; Machiraju, R.; Bergdall, V.K.; Sen, C.K. Tocotrienol vitamin E protects against preclinical canine ischemic stroke by inducing arteriogenesis. J. Cereb. Blood Flow Metab., 2011, 31, 2218-2230.
58. Park, H.A.; Kubicki, N.; Gnyawali, S.; Chan, Y.C.; Roy, S.; Khanna, S.; Sen, C.K. Natural vitamin E alpha-tocotrienol protects against ischemic stroke by induction of multidrug resistanceassociated protein 1. Stroke, 2011, 42, 2308-2314.
59. Huang, Y.; Tsang, S.Y.; Yao, X.; Chen, Z.Y. Biological properties of baicalein in cardiovascular system. Curr. Drug Targets Cardiovasc. Haematol. Disord., 2005, 5, 177-184.
60. Deschamps, J.D.; Kenyon, V.A.; Holman, T.R. Baicalein is a potent in vitro inhibitor against both reticulocyte 15-human and platelet 12-human lipoxygenases. Bioorg. Med. Chem., 2006, 14, 4295-4301.
61. Lapchak, P.A.; Maher, P.; Schubert, D.; Zivin, J.A. Baicalein, an antioxidant 12/15-lipoxygenase inhibitor improves clinical rating scores following multiple infarct embolic strokes. Neuroscience, 2007, 150, 585-591.
62. Xu, Y.W.; Sun, L.; Liang, H.; Sun, G.M.; Cheng, Y. 12/15- Lipoxygenase inhibitor baicalein suppresses PPAR gamma expression and nuclear translocation induced by cerebral ischemia/reperfusion. Brain Res., 2010, 1307, 149-157.
63. Hwang, Y.S.; Shin, C.Y.; Huh, Y.; Ryu, J.H. Hwangryun-Hae- Dok-tang (Huanglian-Jie-Du-Tang) extract and its constituents reduce ischemia-reperfusion brain injury and neutrophil infiltration in rats. Life Sci., 2002, 71, 2105-2117.
64. Kenyon, V.; Chorny, I.; Carvajal, W.J.; Holman, T.R.; Jacobson, M.P. Novel human lipoxygenase inhibitors discovered using virtual screening with homology models. J. Med. Chem., 2006, 49, 1356-1363.
65. Yoshida, H.; Yanai, H.; Namiki, Y.; Fukatsu-Sasaki, K.; Furutani, N.; Tada, N. Neuroprotective effects of edaravone: a novel free radical scavenger in cerebrovascular injury. CNS Drug Rev., 2006, 12, 9-20.
66. Lee, B.J.; Egi, Y.; van Leyen, K.; Lo, E.H.; Arai, K. Edaravone, a free radical scavenger, protects components of the neurovascular unit against oxidative stress in vitro. Brain Res., 2010, 1307, 22-27.
67. Abe, K.; Yuki, S.; Kogure, K. Strong attenuation of ischemic and postischemic brain edema in rats by a novel free radical scavenger. Stroke, 1988, 19, 480-485.
68. Yamaguchi, T.; Sano, K.; Takakura, K.; Saito, I.; Shinohara, Y.; Asano, T.; Yasuhara, H. Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Ebselen Study Group. Stroke, 1998, 29, 12-17.
69. Thiyagarajan, M.; Sharma, S.S. Neuroprotective effect of curcumin in middle cerebral artery occlusion induced focal cerebral ischemia in rats. Life Sci., 2004, 74, 969-985.
70. Lee, S.Y.; Kim, C.Y.; Lee, J.J.; Jung, J.G.; Lee, S.R. Effects of delayed administration of (-)-epigallocatechin gallate, a green tea polyphenol on the changes in polyamine levels and neuronal damage after transient forebrain ischemia in gerbils. Brain Res. Bull., 2003, 61, 399-406.
71. Baskaya, M.K.; Hu, Y.; Donaldson, D.; Maley, M.; Rao, A.M.; Prasad, M.R.; Dempsey, R.J. Protective effect of the 5- lipoxygenase inhibitor AA-861 on cerebral edema after transient ischemia. J. Neurosurg., 1996, 85, 112-116.
72. Maier, C.M.; Chan, P.H. Role of superoxide dismutases in oxidative damage and neurodegenerative disorders. Neuroscientist, 2002, 8, 323-334.
73. Jung, J.E.; Kim, G.S.; Chen, H.; Maier, C.M.; Narasimhan, P.; Song, Y.S.; Niizuma, K.; Katsu, M.; Okami, N.; Yoshioka, H.; Sakata, H.; Goeders, C.E.; Chan, P.H. Reperfusion and neurovascular dysfunction in stroke: from basic mechanisms to potential strategies for neuroprotection. Mol. Neurobiol., 2010, 41, 172-179.
74. Weisbrot-Lefkowitz, M.; Reuhl, K.; Perry, B.; Chan, P.H.; Inouye, M.; Mirochnitchenko, O. Overexpression of human glutathione peroxidase protects transgenic mice against focal cerebral ischemia/reperfusion damage. Brain Res. Mol. Brain Res., 1998, 53, 333-338.
75. Gan, Y.; Ji, X.; Hu, X.; Luo, Y.; Zhang, L.; Li, P.; Liu, X.; Yan, F.; Vosler, P.; Gao, Y.; Stetler, R.A.; Chen, J. Transgenic overexpression of peroxiredoxin-2 attenuates ischemic neuronal injury via suppression of a redox-sensitive pro-death signaling pathway. Antioxid. Redox Signal., 2012, 17, 719-732.
76. Anderson, M.F.; Nilsson, M.; Eriksson, P.S.; Sims, N.R. Glutathione monoethyl ester provides neuroprotection in a rat model of stroke. Neurosci. Lett., 2004, 354, 163-165.
77. Serhan, C.N.; Yacoubian, S.; Yang, R. Anti-inflammatory and proresolving lipid mediators. Annu. Rev. Pathol., 2008, 3, 279-312.
78. Ye, X.H.; Wu, Y.; Guo, P.P.; Wang, J.; Yuan, S.Y.; Shang, Y.; Yao, S.L. Lipoxin A4 analogue protects brain and reduces inflammation in a rat model of focal cerebral ischemia reperfusion. Brain Res., 2010, 1323, 174-183.
79. Bazan, N.G.; Eady, T.N.; Khoutorova, L.; Atkins, K.D.; Hong, S.; Lu, Y.; Zhang, C.; Jun, B.; Obenaus, A.; Fredman, G.; Zhu, M.; Winkler, J.W.; Petasis, N.A.; Serhan, C.N.; Belayev, L. Novel aspirin-triggered neuroprotectin D1 attenuates cerebral ischemic injury after experimental stroke. Exp. Neurol., 2012, 236, 122-130.
80. Serhan, C.N.; Fredman, G.; Yang, R.; Karamnov, S.; Belayev, L.S.; Bazan, N.G.; Zhu, M.; Winkler, J.W.; Petasis, N.A. Novel proresolving aspirin-triggered DHA pathway. Chem. Biol., 2011, 18, 976-987.
81. Belayev, L.; Khoutorova, L.; Atkins, K.D.; Eady, T.N.; Hong, S.; Lu, Y.; Obenaus, A.; Bazan, N.G. Docosahexaenoic acid therapy of experimental ischemic stroke. Transl. Stroke Res., 2011, 2, 33-41.
82. Belayev, L.; Khoutorova, L.; Atkins, K.D.; Bazan, N.G. Robust docosahexaenoic acid-mediated neuroprotection in a rat model of transient, focal cerebral ischemia. Stroke, 2009, 40, 3121-3126.
83. Marcheselli, V.L.; Hong, S.; Lukiw, W.J.; Tian, X.H.; Gronert, K.; Musto, A.; Hardy, M.; Gimenez, J.M.; Chiang, N.; Serhan, C.N.; Bazan, N.G. Novel docosanoids inhibit brain ischemia-reperfusionmediated leukocyte infiltration and pro-inflammatory gene expression. J. Biol. Chem., 2003, 278, 43807-43817.
84. Kitagawa, K.; Matsumoto, M.; Hori, M. Cerebral ischemia in 5- lipoxygenase knockout mice. Brain Res., 2004, 1004, 198-202.
85. Ciceri, P.; Rabuffetti, M.; Monopoli, A.; Nicosia, S. Production of leukotrienes in a model of focal cerebral ischaemia in the rat. Br. J. Pharmacol., 2001, 133, 1323-1329.
86. Helgadottir, A.; Manolescu, A.; Thorleifsson, G.; Gretarsdottir, S.; Jonsdottir, H.; Thorsteinsdottir, U.; Samani, N.J.; Gudmundsson, G.; Grant, S.F.; Thorgeirsson, G.; Sveinbjornsdottir, S.; Valdimarsson, E.M.; Matthiasson, S.E.; Johannsson, H.; Gudmundsdottir, O.; Gurney, M.E.; Sainz, J.; Thorhallsdottir, M.; Andresdottir, M.; Frigge, M.L.; Topol, E.J.; Kong, A.; Gudnason, V.; Hakonarson, H.; Gulcher, J.R.; Stefansson, K. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat. Genet., 2004, 36, 233-239.
87. Domingues-Montanari, S.; Fernandez-Cadenas, I.; del Rio-Espinola, A.; Corbeto, N.; Krug, T.; Manso, H.; Gouveia, L.; Sobral, J.; Mendioroz, M.; Fernandez-Morales, J.; Alvarez-Sabin, J.; Ribo, M.; Rubiera, M.; Obach, V.; Marti-Fabregas, J.; Freijo, M.; Serena, J.; Ferro, J.M.; Vicente, A.M.; Oliveira, S.A.; Montaner, J. Association of a genetic variant in the ALOX5AP with higher risk of ischemic stroke: a case-control, meta-analysis and functional study. Cerebrovasc. Dis., 2010, 29, 528-537.
88. Barral, S.; Fernandez-Cadenas, I.; Bis, J.C.; Montaner, J.; Ikram, A.M.; Launer, L.J.; Fornage, M.; Schmidt, H.; Brickman, A.M.; Seshadri, S.; Mayeux, R. No association of ALOX5AP polymorphisms with risk of MRI-defined brain infarcts. Neurobiol. Aging, 2012, 33, 629 e1-e3.
89. Bevan, S.; Dichgans, M.; Wiechmann, H.E.; Gschwendtner, A.; Meitinger, T.; Markus, H.S. Genetic variation in members of the leukotriene biosynthesis pathway confer an increased risk of ischemic stroke: a replication study in two independent populations. Stroke, 2008, 39, 1109-1114.
90. Helgadottir, A.; Manolescu, A.; Helgason, A.; Thorleifsson, G.; Thorsteinsdottir, U.; Gudbjartsson, D.F.; Gretarsdottir, S.; Magnusson, K.P.; Gudmundsson, G.; Hicks, A.; Jonsson, T.; Grant, S.F.; Sainz, J.; O'Brien, S.J.; Sveinbjornsdottir, S.; Valdimarsson, E.M.; Matthiasson, S.E.; Levey, A.I.; Abramson, J.L.; Reilly, M.P.; Vaccarino, V.; Wolfe, M.L.; Gudnason, V.; Quyyumi, A.A.; Topol, E.J.; Rader, D.J.; Thorgeirsson, G.; Gulcher, J.R.; Hakonarson, H.; Kong, A.; Stefansson, K. A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat. Genet., 2006, 38, 68-74.
91. Schneider, C.; Strayhorn, W.D.; Brantley, D.M.; Nanney, L.B.; Yull, F.E.; Brash, A.R. Upregulation of 8-lipoxygenase in the dermatitis of IkappaB-alpha-deficient mice. J. Invest. Dermatol., 2004, 122, 691-698.
92. Funk, C.D.; Chen, X.S.; Johnson, E.N.; Zhao, L. Lipoxygenase genes and their targeted disruption. Prostaglandins Other Lipid Mediat., 2002, 68-69, 303-312.
93. Yeung, J.; Holinstat, M. 12-lipoxygenase: a potential target for novel anti-platelet therapeutics. Cardiovasc. Hematol. Agents Med. Chem., 2011, 9, 154-164.
94. Deschamps, J.D.; Gautschi, J.T.; Whitman, S.; Johnson, T.A.; Gassner, N.C.; Crews, P.; Holman, T.R. Discovery of platelet-type 12-human lipoxygenase selective inhibitors by high-throughput screening of structurally diverse libraries. Bioorg. Med. Chem., 2007, 15, 6900-6908.
95. Yeung, J.; Apopa, P.L.; Vesci, J.; Kenyon, V.; Rai, G.; Jadhav, A.; Simeonov, A.; Holman, T.R.; Maloney, D.J.; Boutaud, O.; Holinstat, M. Protein kinase C regulation of 12-lipoxygenasemediated human platelet activation. Mol. Pharmacol., 2012, 81, 420-430.
96. Kishimoto, K.; Li, R.C.; Zhang, J.; Klaus, J.A.; Kibler, K.K.; Dore, S.; Koehler, R.C.; Sapirstein, A. Cytosolic phospholipase A2 alpha amplifies early cyclooxygenase-2 expression, oxidative stress and MAP kinase phosphorylation after cerebral ischemia in mice. J. Neuroinflammation, 2010, 7, 42.
97. Bonventre, J.V.; Huang, Z.; Taheri, M.R.; O'Leary, E.; Li, E.; Moskowitz, M.A.; Sapirstein, A. Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A2. Nature, 1997, 390, 622-625.
98. Nito, C.; Kamada, H.; Endo, H.; Niizuma, K.; Myer, D.J.; Chan, P.H. Role of the p38 mitogen-activated protein kinase/cytosolic phospholipase A2 signaling pathway in blood-brain barrier disruption after focal cerebral ischemia and reperfusion. J. Cereb. Blood Flow Metab., 2008, 28, 1686-1696.
99. Massot, A.; Pelegri, D.; Penalba, A.; Arenillas, J.; Boada, C.; Giralt, D.; Ribo, M.; Molina, C.A.; Rosell, A.; Alvarez-Sabin, J.; Chacon, P.; Rovira, A.; Delgado, P. Montaner, J. Lipoproteinassociated phospholipase A2 testing usefulness among patients with symptomatic intracranial atherosclerotic disease. Atherosclerosis, 2011, 218, 181-187.
100. Gorelick, P.B. Lipoprotein-associated phospholipase A2 and risk of stroke. Am. J. Cardiol., 2008, 101, 34F-40F.
101. Elkind, M.S. Inflammatory markers and stroke. Curr. Cardiol. Rep., 2009, 11, 12-20.
102. Muralikrishna Adibhatla, R.; Hatcher, J.F. Phospholipase A2, reactive oxygen species, and lipid peroxidation in cerebral ischemia. Free Radic. Biol. Med., 2006, 40, 376-387.
103. Kolko, M.; de Turco, E.B.; Diemer, N.H.; Bazan, N.G. Secretory phospholipase A2-mediated neuronal cell death involves glutamate ionotropic receptors. Neuroreport, 2002, 13, 1963-1966.
104. Umemura, K.; Kato, I.; Hirashima, Y.; Ishii, Y.; Inoue, T.; Aoki, J.; Kono, N.; Oya, T.; Hayashi, N.; Hamada, H.; Endo, S.; Oda, M.; Arai, H.; Kinouchi, H.; Hiraga, K. Neuroprotective role of transgenic PAF-acetylhydrolase II in mouse models of focal cerebral ischemia. Stroke, 2007, 38, 1063-1068.
105. Iadecola, C.; Niwa, K.; Nogawa, S.; Zhao, X.; Nagayama, M.; Araki, E.; Morham, S.; Ross, M.E. Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc. Natl. Acad. Sci. USA, 2001, 98, 1294-1299.
106. Candelario-Jalil, E. Nimesulide as a promising neuroprotectant in brain ischemia: new experimental evidences. Pharmacol. Res., 2008, 57, 266-273.
107. Iadecola, C.; Sugimoto, K.; Niwa, K.; Kazama, K.; Ross, M.E. Increased susceptibility to ischemic brain injury in cyclooxygenase-1-deficient mice. J. Cereb. Blood Flow Metab., 2001, 21, 1436-1441.
108. Aid, S.; Bosetti, F. Targeting cyclooxygenases-1 and -2 in neuroinflammation: Therapeutic implications. Biochimie, 2011, 93, 46-51.
109. Stark, D.T.; Bazan, N.G. Synaptic and extrasynaptic NMDA receptors differentially modulate neuronal cyclooxygenase-2 function, lipid peroxidation, and neuroprotection. J. Neurosci., 2011, 31, 13710-13721.
110. Grosser, T.; Yu, Y.; Fitzgerald, G.A. Emotion recollected in tranquility: lessons learned from the COX-2 saga. Annu. Rev. Med., 2010, 61, 17-33.
111. Cannon, C.P.; Cannon, P.J. Physiology. COX-2 inhibitors and cardiovascular risk. Science, 2012, 336, 1386-1387.
112. Iadecola, C.; Gorelick, P.B. The Janus face of cyclooxygenase-2 in ischemic stroke: shifting toward downstream targets. Stroke, 2005, 36, 182-185.
113. Andreasson, K. Emerging roles of PGE2 receptors in models of neurological disease. Prostagland. Other Lipid Mediat., 2010, 91, 104-112.
114. Kim, Y.T.; Moon, S.K.; Maruyama, T.; Narumiya, S.; Dore, S. Prostaglandin FP receptor inhibitor reduces ischemic brain damage and neurotoxicity. Neurobiol. Dis., 2012, 48, 58-65.
115. Ahmad, A.S.; Ahmad, M.; Maruyama, T.; Narumiya, S.; Dore, S. Prostaglandin D2 DP1 receptor is beneficial in ischemic stroke and in acute exicitotoxicity in young and old mice. Age (Dordr.), 2010, 32, 271-282.
116. Liu, M.; Hurn, P.D.; Alkayed, N.J. Cytochrome P450 in neurological disease. Curr. Drug Metab., 2004, 5, 225-234.
117. Imig, J.D.; Simpkins, A.N.; Renic, M.; Harder, D.R. Cytochrome P450 eicosanoids and cerebral vascular function. Expert Rev. Mol. Med., 2011, 13, e7.
118. O'Collins, V.E.; Macleod, M.R.; Donnan, G.A.; Horky, L.L.; van der Worp, B.H.; Howells, D.W. 1,026 experimental treatments in acute stroke. Ann. Neurol., 2006, 59, 467-477.
119. Donnan, G.A.; Davis, S.M. Neuroprotection: still achievable in humans. Stroke, 2008, 39, 525.
120. Savitz, S.I.; Schabitz, W.R. A Critique of SAINT II: wishful thinking, dashed hopes, and the future of neuroprotection for acute stroke. Stroke, 2008, 39, 1389-1391.
121. Ginsberg, M.D. Neuroprotection for ischemic stroke: past, present and future. Neuropharmacology, 2008, 55, 363-389.
122. Hussain, M.S.; Shuaib, A. Research into neuroprotection must continue but with a different approach. Stroke, 2008, 39, 521-522.
123. Rother, J. Neuroprotection does not work! Stroke, 2008, 39, 523-524.
124. Chen, R.L.; Balami, J.S.; Esiri, M.M.; Chen, L.K.; Buchan, A.M. Ischemic stroke in the elderly: an overview of evidence. Nat. Rev. Neurol., 2010, 6, 256-265.